Investigating treatments for lethal prostate cancer linked to DNA damage repair issues
Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer
This study is looking at how changes in certain genes, especially BRCA2, might make prostate cancer harder to treat with hormone therapy, and it aims to find new ways to help patients by testing a combination of targeted radiation and other treatments for those with specific gene issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11045016 on NIH RePORTER |
What this research studies
This research focuses on understanding how alterations in DNA damage repair genes, particularly BRCA2, contribute to resistance against androgen deprivation therapy (ADT) in prostate cancer. By using advanced CRISPR technology, the study aims to explore the molecular mechanisms that lead to treatment resistance and the progression of lethal prostate cancer. The researchers will analyze a wide range of DDR-associated genes to identify potential therapeutic targets and evaluate the effectiveness of combining PSMA-targeted radiotherapy with PARP inhibitors in patients with DDR-deficient prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include men diagnosed with advanced prostate cancer who have alterations in DNA damage repair genes, especially BRCA2.
Not a fit: Patients with early-stage prostate cancer or those without alterations in DDR genes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with lethal prostate cancer, particularly those resistant to current therapies.
How similar studies have performed: Previous research has shown promising results in targeting DNA damage repair pathways in cancer, indicating potential for success with this novel approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Chakraborty, Goutam — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chakraborty, Goutam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.